Efficacy News and Research

RSS

Research to Prevent Blindness, IRRF partner to advance knowledge about AMD

Research to Prevent Blindness, the leading eye research foundation, is partnering with the International Retinal Research Foundation to advance knowledge about age-related macular degeneration (AMD) through novel stem cell research.

5 Dec 2014

Phase IIb trial shows platinum-resistant ovarian patients treated with PM1183 live longer

Zeltia announces today that its pharmaceutical division PharmaMar has data from a group of 33 randomized patients with platinum-resistant ovarian cancer demonstrating that PM1183 shows a significantly superior median overall survival compared to topotecan.

4 Dec 2014

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients.

4 Dec 2014

MRIGlobal awarded $3 million contract to provide HPV vaccine

MRIGlobal today announced that it has been awarded a $3 million contract amendment from the National Cancer Institute's PREVENT Cancer Program to provide a vaccine for the Human Papillomavirus or HPV, the most common sexually transmitted infection in the United States. MRIGlobal will lead a team that will produce the vaccine to be used in a Phase I clinical trial.

4 Dec 2014

Thomson Reuters, Linguamatics launch Cortellis Informatics Clinical Text Analytics for I2E

The Intellectual Property & Science business of Thomson Reuters, the world leader in intelligent information for businesses and professionals, today announced a collaboration with Linguamatics to advance pharmaceutical clinical trial research and development (R&D) with the launch of Cortellis Informatics Clinical Text Analytics for I2E.

4 Dec 2014

BeyondSpring Pharmaceuticals plans to initiate Plinabulin Phase 3 pivotal trial in NSCLC patients

BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it plans to initiate a Phase 3 pivotal trial of lead product candidate, Plinabulin, in patients with non-small cell lung cancer (NSCLC) in the first quarter of 2015.

4 Dec 2014

Oncologists examine efficacy of rose bengal against cancer

Rose Bengal has been around for decades starting as a way to dye wool. Originally used in medicine as a stain for ophthalmologists, it has a solid safety record going back to the 1930s. Recently, oncologists have examined its efficacy against cancer, specifically melanoma.

4 Dec 2014

$TxCell enrolls first patient in Ovasave phase IIb trial for treatment of refractory Crohn’s disease$

TxCell enrolls first patient in Ovasave phase IIb trial for treatment of refractory Crohn’s disease

TxCell SA, a biotechnology company developing novel and innovative, cost-effective personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it has enrolled the first patient in its phase IIb clinical trial of its lead product Ovasave in refractory Crohn’s disease.

4 Dec 2014

Endocrinologist examines benefits and harms of testosterone therapy

An article in the latest edition of Australian Prescriber looks at the prescribing of testosterone, often used for ‘male menopause’ symptoms such as reduced energy, poor concentration and increased body fat. Over the past decade there has been a steep rise in the amount of testosterone dispensed in Australia and globally.

4 Dec 2014

New technology reveals cellular gene transcription process in detail

A new technology that reveals cellular gene transcription in greater detail has been developed by Dr. Daniel Kaufmann of the University of Montreal Hospital Research Centre and the research team he directed. "This new research tool offers us a more profound view of the immune responses that are involved in a range of diseases, such as HIV infection. At the level of gene transcription, this had been difficult, complex and costly to do with current technologies, such as microscopy," explained the University of Montreal professor.

4 Dec 2014

PulmoFlow's nebulized drug and device combination gets FDA approval for cystic fibrosis

On Tuesday, the FDA granted final approval of PulmoFlow, Inc.'s New Drug Application for Kitabis Pak – a co-packaging of generic tobramycin inhalation solution with a PARI LC PLUS Nebulizer. This is the first nebulized drug and device combination to be approved for patients with cystic fibrosis.

3 Dec 2014

Garmatex, Diagnomics partner to develop healthcare products to prevent hospital-acquired infections

Garmatex Technologies, Inc., a leading inventor of performance fabric and apparel solution-focused technologies, has signed a Letter of Intent ("LOI") for a five year term with Diagnomics Inc., a biotech company that provides next-generation healthcare solutions from personal genomics.

3 Dec 2014

Study explores use of bisphosphonates for men receiving androgen deprivation therapy

Although some guidelines recommend use of bisphosphonates (a class of drugs used to strengthen bone) for men on androgen deprivation therapy, an analysis finds that prescriptions for these drugs remains low, even for those men at high risk of subsequent fractures, according to a study in the December 3 issue of JAMA.

3 Dec 2014

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis will highlight more than 250 abstracts demonstrating advances in blood and breast cancer research at the upcoming American Society of Hematology (ASH) annual meeting December 6-9, and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) December 9-13.

2 Dec 2014

Alport syndrome: an interview with Dr Paul Grint, CMO, Regulus

Alport Syndrome was first described by a physician called Cecil Alport, back in the late 1920s. It's a genetic disease that affects a certain type of collagen involved in the functioning of the kidney, the ear, and the eye.

1 Dec 2014

DEX implant improves visual acuity in patients with diabetic macular oedema

Patients with diabetic macular oedema benefit from intravitreal dexamethasone implants, a study shows, with the treatment improving best-corrected visual acuity with an acceptable safety profile.

1 Dec 2014

Eylea receives Health Canada approval for treatment of CRVO and DME

Bayer Inc. announced today that it has received approval from Health Canada for Eylea (aflibercept, solution for intravitreal injection) for the treatment of diabetic macular edema (DME). This new indication comes just six weeks following the October 16th approval of Eylea for the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO).

1 Dec 2014

Eli Lilly, AstraZeneca begin AZD3293 Phase II/III study for treatment of early Alzheimer's disease

Eli Lilly and Company and AstraZeneca today announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease.

1 Dec 2014

Grand Challenges Canada announces $1.2 million in grant for 11 new global health innovations

Grand Challenges Canada, funded by the Government of Canada, today announced $1.2 million in funding for 11 new global health innovations implemented in member states of La Francophonie.

29 Nov 2014

Pivotal Therapeutics announces accomplishments, financial results for Q3 2014

Pivotal Therapeutics Inc., ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its accomplishments and financial results for the three months ended September 30, 2014.

29 Nov 2014

Efficacy News and Research

Research to Prevent Blindness, IRRF partner to advance knowledge about AMD

Phase IIb trial shows platinum-resistant ovarian patients treated with PM1183 live longer

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

MRIGlobal awarded $3 million contract to provide HPV vaccine

Thomson Reuters, Linguamatics launch Cortellis Informatics Clinical Text Analytics for I2E

BeyondSpring Pharmaceuticals plans to initiate Plinabulin Phase 3 pivotal trial in NSCLC patients

Oncologists examine efficacy of rose bengal against cancer

TxCell enrolls first patient in Ovasave phase IIb trial for treatment of refractory Crohn’s disease

Endocrinologist examines benefits and harms of testosterone therapy

New technology reveals cellular gene transcription process in detail

PulmoFlow's nebulized drug and device combination gets FDA approval for cystic fibrosis

Garmatex, Diagnomics partner to develop healthcare products to prevent hospital-acquired infections

Study explores use of bisphosphonates for men receiving androgen deprivation therapy

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Alport syndrome: an interview with Dr Paul Grint, CMO, Regulus

DEX implant improves visual acuity in patients with diabetic macular oedema

Eylea receives Health Canada approval for treatment of CRVO and DME

Eli Lilly, AstraZeneca begin AZD3293 Phase II/III study for treatment of early Alzheimer's disease

Grand Challenges Canada announces $1.2 million in grant for 11 new global health innovations

Pivotal Therapeutics announces accomplishments, financial results for Q3 2014

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News